medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2001, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2001; 10 (1)

Open and prospective study to evaluate the security and efficacy with the combination of loratadine/pseudoephedrine in solution in pediatric population from 2 to 8 years old with allergic rhinitis

Fregoso OA

Language: Spanish
References: 10
Page: 6-11
PDF size: 364.87 Kb.


ABSTRACT

An open and prospective study was developed in a 2-8 years old pediatric population diagnosed with allergic rhinitis. Every patient was given a 0.5 mg of loratadine/6.0 mg of pseudoephedrine combination in solution every 12 hours during 7 days. The clinical findings that were studied included: sneezing, conjunctival pruritus, nasal congestion, sleeping disorders, tearing, rhinorrea and general malaise. All the possible adverse reactions caused by the administration of this combination were also studied. The clinical study proved that this new combination of drug, 0.5 mg of loratadine/6.0 mg of pseudoephedrine, is successful in the treatment of allergic rhinitis with the presentation of minimal side effects.


REFERENCES

  1. Mc Fadden, Gungor A, Ng B, Mamikoglu B, Moinuddin R, Corey J. Loratadine/pseudoephedrine for nasal symptoms in seasonal allergic rhinitis. A double-blind, placebo-controlled study. Ear Throat J 2000; 79: 254-67.

  2. Corren J, Harris A, Aaronson D, Beaucher W et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100: 781-8.

  3. Nolen T. Sedative effects of antihistamines: Safety, performance, learning, and quality of life. Clin Ther 1997; 19: 39-55.

  4. Bedard PM, Del Carpio J, Drouin MA et al. Onset of action of loratadine and placebo and other efficacy variables in patients with seasonal allergic rhinitis. Clin Ther 1992; 14: 268-275.

  5. Rachelefsky G. Pharmacologic management of allergic rhinitis. J Allergy Clin Immunol 1998; 101: S367-9.

  6. Querino L. Loratadine. Drugdex Drug Evaluations 2000.

  7. Trejo Tapia D, Ulloa S. Loratadina-pseudoefedrina: hacia un mejor control sintomático de la rinitis alérgica. Invest Méd Int 1993; 20: 76-79.

  8. Sánchez M, Trejo Tapia D. Eficacia y seguridad de la loratadina más pseudoefedrina, solución pediátrica, en niños con rinitis alérgica. Invest Méd Int 1993; 20: 92-97.

  9. Dávila Velázquez J, Sánchez García M. Evaluación terapéutica de un antihistamínico asociado a pseudoefedrina en niños con rinitis alérgica perenne. Invest Méd Int 1993; 20: 85-91.

  10. González Gámez J, García Reyes G, Ramírez M, Santoyo S, Sánchez García M. Estudio comparativo sobre eficacia y seguridad de dos antihistamínicos de nueva generación asociados a pseudoefedrina en niños con rinitis alérgica. Invest Méd Int 1993; 20: 80-84.




2020     |     www.medigraphic.com